Published in Cancer Weekly, July 29th, 1996
Empty 22-nm subviral particles purified from the plasma of chronic carriers were the first HBV vaccines to be used in humans. The second, and current generation of HBV vaccines consists of similar subviral particles which have been produced as recombinant proteins in stably transfected eukaryotic cell lines.
In spite of their high efficacy, the current subunit HBV vaccines are not widely used in developing countries owing to the high...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.